Osteoarthritis Clinical Studies

You have full text access to this OnlineOpen article

Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: The study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial

  1. André Kahan1,†,*,
  2. Daniel Uebelhart2,
  3. Florent De Vathaire3,
  4. Pierre D. Delmas1,2,3,4,‡,§,
  5. Jean-Yves Reginster4,¶

Article first published online: 29 JAN 2009

DOI: 10.1002/art.24255

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 60, Issue 2, pages 524–533, February 2009

Additional Information

How to Cite

Kahan, A., Uebelhart, D., De Vathaire, F., Delmas, P. D. and Reginster, J.-Y. (2009), Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: The study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism, 60: 524–533. doi: 10.1002/art.24255

Author Information

  1. 1

    University of Paris Descartes, and Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris, France

  2. 2

    University Hospital Zurich, Zurich, Switzerland

  3. 3

    INSERM Research Unit 605, Institut Gustave-Roussy, and University of Paris XI, Villejuif, France

  4. 4

    University of Liege, Liege, Belgium

  1. †

    Dr. Kahan has received consulting and/or speaking fees (less than $10,000) from IBSA.

  2. ‡

    Dr. Delmas has received consulting and/or speaking fees from Acceleron, Amgen, Eli Lilly, GlaxoSmithKline, Merck, Sharpe, and Dohme, Novartis, Nycomed, Organon, Pfizer, Procter & Gamble, Sanofi-Aventis, Servier, Wyeth, and Zelos Therapeutics (less than $10,000 each) and from Roche (more than $10,000); he has also received research grants from Procter & Gamble, Eli Lilly, and Amgen.

  3. §

    Dr. Delmas is deceased.

  4. Dr. Reginster has received consulting fees and/or has served on paid advisory boards for Servier, Novartis, Negma, Eli Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merck, Nycomed, NPS Pharmaceuticals, Theramex, and UCB; has received speaking fees from Merck, Sharpe, and Dohme, Eli Lilly, Rottapharm, IBSA, Genévrier, Novartis, Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Theramex, Nycomed, and Novo Nordisk; and has received grant support from Bristol-Myers Squibb, Merck, Sharpe, and Dohme, Rottapharm, Teva, Eli Lilly, Novartis, Roche, GlaxoSmithKline, Amgen, and Servier (less than $10,000 each).

*Service de Rhumatologie A, Hôpital Cochin, 27 Rue du Faubourg St. Jacques, 75014 Paris, France

Publication History

  1. Issue published online: 29 JAN 2009
  2. Article first published online: 29 JAN 2009
  3. Manuscript Accepted: 17 OCT 2008
  4. Manuscript Received: 18 JUL 2008

Funded by

  • IBSA, Lugano, Switzerland
  • Genévrier Laboratories, Sophia-Antipolis, France

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (117K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Noriyuki Kanzaki, Kayo Saito, Akifumi Maeda, Yoshinori Kitagawa, Yoshinobu Kiso, Keita Watanabe, Akihito Tomonaga, Isao Nagaoka, Hideyo Yamaguchi, Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled study, Journal of the Science of Food and Agriculture, 2012, 92, 4
    Direct Link:
  2. 2
    Mirela-Onita Iovu, Lucie Héroux, Josep Vergés, Eulália Montell, Jacques Paiement, Patrick du Souich, Effect of chondroitin sulfate on turpentine-induced down-regulation of CYP1A2 and CYP3A6, Carbohydrate Research, 2012,

    CrossRef

  3. 3
    Cyrus Cooper, Jean-Yves Reginster, Roland Chapurlat, Claus Christiansen, Harry Genant, Nicholas Bellamy, William Bensen, Federico Navarro, Janusz Badurski, Evgeny Nasonov, Xavier Chevalier, Philip N. Sambrook, Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial, Current Medical Research and Opinion, 2012, 28, 2, 231

    CrossRef

  4. 4
    Sean T. Hurley, Gillian L. Hatfield Murdock, William D. Stanish, Cheryl L. Hubley-Kozey, Is There a Dose Response for Valgus Unloader Brace Usage on Knee Pain, Function, and Muscle Strength?, Archives of Physical Medicine and Rehabilitation, 2012, 93, 3, 496

    CrossRef

  5. 5
    Hector L. Lopez, Nutritional Interventions to Prevent and Treat Osteoarthritis. Part II: Focus on Micronutrients and Supportive Nutraceuticals, PM&R, 2012, 4, 5, S155

    CrossRef

  6. 6
    R.L. Manno, C.O. Bingham, S. Paternotte, L. Gossec, H. Halhol, G. Giacovelli, L. Rovati, S.A. Mazzuca, D.O. Clegg, H. Shi, E. Tajana Messi, A. Lanzarotti, M. Dougados, OARSI–OMERACT initiative: defining thresholds for symptomatic severity and structural changes in disease modifying osteoarthritis drug (DMOAD) clinical trials, Osteoarthritis and Cartilage, 2012, 20, 2, 93

    CrossRef

  7. 7
    Giovanni V. Coppa, Francesca Maccari, Lucia Zampini, Lucia Santoro, Tiziana Galeazzi, Orazio Gabrielli, Nicola Volpi, Structural characterisation of chondroitin sulphate from Italian cheese Parmigiano-Reggiano, Food Chemistry, 2012, 134, 1, 195

    CrossRef

  8. 8
    Nicola Volpi, Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule, Inflammopharmacology, 2011, 19, 6, 299

    CrossRef

  9. 9
    Pascal Richette, Approches thérapeutiques de l’arthrose, Thérapie, 2011, 66, 5, 383

    CrossRef

  10. 10
    K. Bauerova, S. Ponist, V. Kuncirova, D. Mihalova, E. Paulovicova, N. Volpi, Chondroitin sulfate effect on induced arthritis in rats, Osteoarthritis and Cartilage, 2011, 19, 11, 1373

    CrossRef

  11. 11
    Jörg Jerosch, Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids, International Journal of Rheumatology, 2011, 2011, 1

    CrossRef

  12. 12
    Gloria L Matthews, David J Hunter, Emerging drugs for osteoarthritis, Expert Opinion on Emerging Drugs, 2011, 16, 3, 479

    CrossRef

  13. 13
    Johanne Martel-Pelletier, Lukas M. Wildi, Jean-Pierre Pelletier, Future therapeutics for osteoarthritis, Bone, 2011,

    CrossRef

  14. 14
    Karla L. Miller, Daniel O. Clegg, Glucosamine and Chondroitin Sulfate, Rheumatic Disease Clinics of North America, 2011, 37, 1, 103

    CrossRef

  15. 15
    Elizaveta Kon, Giuseppe Filardo, Matej Drobnic, Henning Madry, Mislav Jelic, Niek Dijk, Stefano Della Villa, Non-surgical management of early knee osteoarthritis, Knee Surgery, Sports Traumatology, Arthroscopy, 2011, 20, 3, 436

    CrossRef

  16. 16
    Johannes WJ Bijlsma, Francis Berenbaum, Floris PJG Lafeber, Osteoarthritis: an update with relevance for clinical practice, The Lancet, 2011, 377, 9783, 2115

    CrossRef

  17. 17
    W.M. Reichmann, J.F. Maillefert, D.J. Hunter, J.N. Katz, P.G. Conaghan, E. Losina, Responsiveness to change and reliability of measurement of radiographic joint space width in osteoarthritis of the knee: a systematic review, Osteoarthritis and Cartilage, 2011, 19, 5, 550

    CrossRef

  18. 18
    Cem Gabay, Carole Medinger-Sadowski, Danielle Gascon, Frank Kolo, Axel Finckh, Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: A randomized, double-blind, placebo-controlled clinical trial at a single center, Arthritis & Rheumatism, 2011, 63, 11
    Direct Link:
  19. 19
    E. Sahinbegovic, G. Schett, Therapiestrategien der erosiven Fingerpolyarthrose, Der Internist, 2011, 52, 6, 682

    CrossRef

  20. 20
    DONNA M. URQUHART, JEPHTAH F. L. TOBING, FAHAD S. HANNA, PATRICIA BERRY, ANITA E. WLUKA, CHANGHAI DING, FLAVIA M. CICUTTINI, What Is the Effect of Physical Activity on the Knee Joint? A Systematic Review, Medicine & Science in Sports & Exercise, 2011, 43, 3, 432

    CrossRef

  21. 21
    Muneaki Ishijima, Hisashi Kurosawa, Haruka Kaneko, Kazuo Kaneko, Arthritis, 2011,

    CrossRef

  22. 22
    Keisuke Imada, Hideki Oka, Daisuke Kawasaki, Naoyoshi Miura, Takashi Sato, Akira Ito, Anti-arthritic Action Mechanisms of Natural Chondroitin Sulfate in Human Articular Chondrocytes and Synovial Fibroblasts, Biological & Pharmaceutical Bulletin, 2010, 33, 3, 410

    CrossRef

  23. 23
    J. Egea, A.G. García, J. Verges, E. Montell, M.G. López, Antioxidant, antiinflammatory and neuroprotective actions of chondroitin sulfate and proteoglycans, Osteoarthritis and Cartilage, 2010, 18, S24

    CrossRef

  24. 24
    Dania Buzzega, Francesca Maccari, Nicola Volpi, Determination of molecular mass values of chondroitin sulfates by fluorophore-assisted carbohydrate electrophoresis (FACE), Journal of Pharmaceutical and Biomedical Analysis, 2010, 51, 4, 969

    CrossRef

  25. 25
    I. Möller, M. Pérez, J. Monfort, P. Benito, J. Cuevas, C. Perna, G. Doménech, M. Herrero, E. Montell, J. Vergés, Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study, Osteoarthritis and Cartilage, 2010, 18, S32

    CrossRef

  26. 26
    Déborah Gensburger, Jean-Paul Roux, Monique Arlot, Elisabeth Sornay-Rendu, Philippe Ravaud, Roland Chapurlat, Influence of blinding sequence of radiographs on the reproducibility and sensitivity to change of joint space width measurement in knee osteoarthritis, Arthritis Care & Research, 2010, 62, 12
    Direct Link:
  27. 27
    M. Vallières, P. du Souich, Modulation of inflammation by chondroitin sulfate, Osteoarthritis and Cartilage, 2010, 18, S1

    CrossRef

  28. 28
    W. Zhang, G. Nuki, R.W. Moskowitz, S. Abramson, R.D. Altman, N.K. Arden, S. Bierma-Zeinstra, K.D. Brandt, P. Croft, M. Doherty, M. Dougados, M. Hochberg, D.J. Hunter, K. Kwoh, L.S. Lohmander, P. Tugwell, OARSI recommendations for the management of hip and knee osteoarthritis, Osteoarthritis and Cartilage, 2010, 18, 4, 476

    CrossRef

  29. 29
    David J. Hunter, Pharmacologic therapy for osteoarthritis—the era of disease modification, Nature Reviews Rheumatology, 2010, 7, 1, 13

    CrossRef

  30. 30
    M.C. Hochberg, Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration, Osteoarthritis and Cartilage, 2010, 18, S28

    CrossRef

  31. 31
    Nancy E. Lane, Thomas J. Schnitzer, Charles A. Birbara, Masoud Mokhtarani, David L. Shelton, Mike D. Smith, Mark T. Brown, Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee, New England Journal of Medicine, 2010, 363, 16, 1521

    CrossRef

  32. 32
    Micronutrients in Health and Disease, 2010,

    CrossRef

  33. 33
    K.D. Rainsford, Importance of pharmaceutical composition and evidence from clinical trials and pharmacological studies in determining effectiveness of chondroitin sulphate and other glycosaminoglycans: a critique, Journal of Pharmacy and Pharmacology, 2009, 61, 10
    Direct Link:
  34. 34
    Jack Challem, Medical Journal Watch: Context and Applications, Alternative and Complementary Therapies, 2009, 15, 3, 156

    CrossRef

  35. 35
    Robert J. Daher, Nadeen O. Chahine, Andrew S. Greenberg, Nicholas A. Sgaglione, Daniel A. Grande, New methods to diagnose and treat cartilage degeneration, Nature Reviews Rheumatology, 2009, 5, 11, 599

    CrossRef

  36. 36
    Nicola Volpi, Quality of different chondroitin sulfate preparations in relation to their therapeutic activity, Journal of Pharmacy and Pharmacology, 2009, 61, 10
    Direct Link:
View Full Article (HTML) Get PDF (117K)